Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00077324
Status:
COMPLETED
Last Update Posted:
2016-07-06
First Post:
2004-02-10
Brief Title:
Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
Use Of Proteomic Analysis Of Serum Samples For Detection Of Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Evaluating specific proteins in the blood may be an effective and noninvasive procedure to help doctors determine if a patient has early non-small cell lung cancer
PURPOSE This clinical trial is studying proteomic profiling to see how well it works in diagnosing non-small cell lung cancer in patients who are undergoing resection for suspicious abnormal stage I lung lesions
PURPOSE This clinical trial is studying proteomic profiling to see how well it works in diagnosing non-small cell lung cancer in patients who are undergoing resection for suspicious abnormal stage I lung lesions
Detailed Description:
OBJECTIVES
Primary
Determine prospectively whether serum proteomic profiling can predict the presence of primary non-small cell lung cancer in patients with clinically suspicious stage I lung lesions who are undergoing lung resection
Secondary
Correlate the serum proteomic profile with pathologic nodal status and histopathologic features of primary lung cancer in these patients
Correlate the initial and follow-up serum proteomic profile with overall and cancer-specific survival of these patients
Correlate changes in the proteomic profile preoperative to postoperative with overall and cancer-specific survival of these patients
Tertiary
Determine whether novel molecular strategies can predict the presence of lung cancer andor the biologic behavior of an individual cancer in these patients
Primary
Determine prospectively whether serum proteomic profiling can predict the presence of primary non-small cell lung cancer in patients with clinically suspicious stage I lung lesions who are undergoing lung resection
Secondary
Correlate the serum proteomic profile with pathologic nodal status and histopathologic features of primary lung cancer in these patients
Correlate the initial and follow-up serum proteomic profile with overall and cancer-specific survival of these patients
Correlate changes in the proteomic profile preoperative to postoperative with overall and cancer-specific survival of these patients
Tertiary
Determine whether novel molecular strategies can predict the presence of lung cancer andor the biologic behavior of an individual cancer in these patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000350123 | REGISTRY | NCI Physician Data Query | None |